Effects of telbivudine re-treatment on seroconversion and liver function in patients with chronic hepatitis B and α-interferon non-response
HUANG Wei
WU Li-juan
JIE Yu-zhou
Abstract：Objective:To analyze the curative effect of telbivudine re-treatment on patients with chronic hepatitis B and α-interferon non-response.Methods:A total of 72 patients with chronic hepatitis B and non-response after 6 months of polyethylene glycol α-interferon therapy in the Xianning City Hospital of Traditional Chinese Medicine were enrolled between October 2020 and October 2022,and they were randomly divided into observation group(36 cases)and control group(36 cases).The control group was treated with entecavir,while observation group was treated with telbivudine for 4 months.The load of serum HBV DNA was detected by real-time fluorescence quantitative PCR.The levels of serum HBsAg and HBeAg were detected by enzyme-linked immunosorbent assay.The levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBIL)were detected by full-automatic biochemical analyzer.The levels of serum hyaluronic acid(HA),type Ⅳ collagen(Ⅳ-C),laminin(LN)and type Ⅲ procollagen(PC-Ⅲ)were detected by chemiluminescence method.The drug resistance sites were detected by reverse hybridization.Results:There was no significant difference in ALT normalization rate,HBV DNA negative conversion rate,HBsAg negative conversion rate and HBeAg negative conversion rate between the treatment group and the control group(χ2 = 0.084,0.215,0,0.348,all P>0.05).After treatment,the levels of ALT,AST,TBIL,LN,HA,Ⅳ-C and PC-Ⅲ in the treatment group(ALT(42.27±6.65)U·L-1,AST(38.32±5.64)U·L-1,TBIL(29.25±4.62)µmol·L-1,LN(184.21±20.61)U·L-1,HA(123.28±13.45)μg·L-1,Ⅳ-C(212.61±22.56)μg·L-1,PC-Ⅲ(129.27±13.34)μg·L-1)were lower than those in the control group((64.65±8.79)U·L-1,(55.76±7.72)U·L-1,(54.81±6.47)µmol·L-1,(249.57±25.83)U·L-1,(166.37±16.56)μg·L-1,(242.39±25.34)μg·L-1,(154.82±15.78)μg·L-1)(t = 12.193,10.945,19.290,11.868,12.119,5.267,7.418,all P<0.05).There was no significant difference in drug resistance rate or total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The curative effect of telbivudine re-treatment is good on patients with chronic hepatitis B and α-interferon non-response,which can effectively improve liver function and liver fibrosis.
Keywords：TelbivudineChronic hepatitis Bα-interferon non-responseLiver functionLiver fibrosis
Publication Date：2023-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 344-347 )